A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.

Sophie Piperno-NeumannM S CarlinoV BoniD LoiratF M SpeetjensJ J ParkE CalvoR D CarvajalM NyakasJ Gonzalez-MaffeX ZhuM D ShirleyT RamkumarA FessehatsionH E BurksP Yerramilli-RaoE Kapiteijn

Published in: British journal of cancer (2023)

These results suggest manageable toxicity and encouraging clinical activity of single-agent LXS196 in patients with MUM.

Keyphrases

protein kinase
squamous cell carcinoma
small cell lung cancer
study protocol
clinical trial
phase iii
oxidative stress
phase ii
open label
skin cancer
double blind